SPC-14 - Targeting Alzheimer’s
Regulatory Pathway & Results
- 505(b)(2) Pathway
- Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University
- SPC-14 has shown reduced hyponeophagia in animal studies
- SPC-14 may reduce behavioral despair
- Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab
Market Opportunity - Alzheimer’s Disease
- 6.5 million Americans suffer from Alzheimer’s and related diseases
- ~1 in 9 Americans 65+ have Alzheimer’s
- U.S. market for relevant drugs expected to reach $5Bn by 2027
SPC-15 - Targeted prophylactic treatment—Stress-induced affective disorders
- Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders
- Increasing stress resilience in military, first responders, and other populations at high risk of PTSD
- Predicting the level of severity or progression such disorders
- Molecular targets for use in drug discovery of innovative treatments
- 26% of Americans 18+ suffer from anxiety, PTSD and other disorders
- This number has escalated post-CV-19
- U.S. market for relevant drugs expected to reach $13Bn by 2027
SP-26 - Time-Released Psi-lo-cybin, Keta-mine
- Deliver Keta-mine or Psi-lo-cybin in a time-released manner
- Will time-release diminish the hallucinogenic effects of these psych-e-delics
- Pre clinical study underway shows Z-pod can hold and distribute Keta-mine
- Efficacy study in animals underway
SPU-16 - CNS Homing Peptide
Regulatory Pathway & Results 505(b)(2) Pathway
- May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord
- May be used for diagnosing and monitoring MS
- Decreases toxicity of existing therapeutics
- Animal study results show much improved delivery of therapeutics and decreased toxicity.
- There are approximately 400,000 Americans and 2.5 million people worldwide with MS
- The most widespread disabling neurological condition of young adults
- Global market for MS drugs expected to reach $25.3Bn by 2027
SPU-21 - Arthritogenic Joint Homing Peptides Utilizing Psi-lo-cybin
- Identify markers of arthritic inflammation in joints
- Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats
- Peptide significantly inhibited arthritic progression in this animal model
- Further studies are underway at UMB
- 1.3Mn U.S. adults suffer from RA
- The most common autoimmune disease in U.S.
- U.S. market for RA drugs expected to reach $63Bn by 2027
Grab more key company details/sources here.
Right now, SILO has several potential catalysts that could provide it with a breakout spark. Here's what to know:
No. 1 SILO Potential Catalyst - Low Float Volatility Could Pop Up On Daily Basis
According to the Yahoo Finance website, SILO has a low float.
The website reports this profile to have approximately 2.57Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more 2023 positive company news help provide a near term spark?
No. 2 SILO Potential Catalyst - Two Awarded Patents Aim To Protect IP's Key Technology
In the last few months, SILO has been awarded two, game-changing patents further helping to protect their IP.
Check them out:
#1. Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psi-lo-cybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication.”
#2. Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
“This patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Based on our latest research with Columbia University on SPC-15, this IP expands the claims of the original patent.”
No. 3 SILO Potential Catalyst - Company Enters Into Game-Changing Agreement To Develop Implant For Fibromyalgia Treatment
Silo Pharma Signs Agreement to Develop First-in-Class Keta-mine Implant Therapeutic
Initial indications are fibromyalgia and chronic pain
ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release keta-mine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
“Alongside our development of SP-26, our novel time-release topical formulation of keta-mine, we are beginning to explore an additional option for treating fibromyalgia using keta-mine-loaded implants,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The outcome of this research will provide additional information and data for our ongoing studies of keta-mine treatments for fibromyalgia and other chronic pain indications.”
Read the full article here.
No. 4 SILO Potential Catalyst - Study's Phase 2 Will Help To Further Investigate Cyclic Peptides In Human Tissue
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue
ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.
Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”
Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).
Read the full article here.
No. 5 SILO Potential Catalyst - "Positive Results" Provide A Spotlight On SP-26 (Continuing Progression To Human Trials)
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of keta-mine. The study results evaluated the feasibility of using a rising dose design or maximum feasibility.
In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen. The study utilized the bioanalytical methods required to perform toxicology studies by the U.S. Food and Drug Administration (FDA) in advance of initiating clinical studies for SP-26.
“Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “We are advancing our work with our regulatory partners to prepare a Pre-Investigational New Drug (IND) package for SP-26 and intend to pursue the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.”
Read the full article here.
SILO Recap - Key Potential Breakout Catalysts To Know Now
No. 1 - Low Float Volatility Could Pop Up On Daily Basis
No. 2 - Two Awarded Patents Aim To Protect IP's Key Technology
No. 3 - Company Enters Into Game-Changing Agreement To Develop Implant For Fibromyalgia Treatment
No. 4 - Study's Phase 2 Will Help To Further Investigate Cyclic Peptides In Human Tissue
No. 5 - "Positive Results" Provide A Spotlight On SP-26 (Continuing Progression To Human Trials)
Coverage is officially initiated on SILO. When time permits, do this: